Located at the heart of one of the most bustling biotechnology, IT and energetics hubs in Poland, our 7,500 square meter R&D and production facility at the Gdansk Science and Technology Park is one of the most modern biotechnology centers in Europe. In Gdansk, we provide process development and GMP production of clinical and medium-scale commercial materials, supported by QC, QA and project management functions.
Customized formulations for drug product can also be developed in-house and subsequently tested for stability according to ICH standards. All processes, including fill & finish, can be scaled up and internally transferred to mammalian and microbial GMP-certified production facilities or to external partners. The facility utilizes scale-down models, as well as high-throughput mini and regular bioreactor systems for parallel screening.
Mammalian: 1 x 50 L, 1 x 250 L, 2 x 1,000 L
Microbial: 1 x 500 L
Located in Poland’s capital, Warsaw, and built to serve the growing global demand for biopharmaceuticals is our commercial-scale GMP production facility for drug substance. It is one of the largest and newest facilities of its kind in Europe.
The site adds significant drug substance manufacturing capacity for both commercial and clinical supply at 2,000 L scale and also includes a range of single use bioreactors from 50-500 L aimed at supporting clients with smaller capacity needs. This means we can support the increasing demand for early stage clinical trial material and orphan drugs at optimal costs.
3 x 500 L, 4 x 2,000 L
Expansion available to 30,000 L
Located in the Utrecht Science Park, a hub for education, research, entrepreneurship and healthcare. The state-of-the-art facility focuses on the development of production cell lines for monoclonal antibodies (mAbs) and other proteins (including laboratory scale processes), as well as the generation of New Biological Entities (NBEs).
We currently employ around 50 personnel at the site, many are industry veterans in early stage development.